UPPSALA, Sweden, Nov. 14, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Flex, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel. With the introduction of Olink® Flex, the […]
Author: Ken Dropiewski
Cardio Diagnostics Holdings Inc CEO Meesha Dogan, Accepted into Forbes Technology Council
Forbes Technology Council Is an Invitation-Only Community for World-Class CIOs, CTOs, and Technology Executives. CHICAGO–(BUSINESS WIRE)–Meesha Dogan, PhD, the CEO of Cardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, has been accepted into Forbes Technology Council, an invitation-only community for world-class CIOs, CTOs, and technology executives. Cardio Diagnostics is a biotechnology […]
Hello Heart Adds Breakthrough Artificial Intelligence (AI) Capabilities to Empower Users to Make Better Choices
Users now have access to deeper insights and personalization to support positive choices regarding their heart health MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses exclusively on heart health, today announced Dot-to-Dot, a new addition to their digital whole heart health program. Dot-to-Dot is a breakthrough feature that […]
Preliminary Data from AAA-SHAPE to be Presented at VEITH 2022
SANTA CLARA, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., developer of custom, proprietary shape memory polymers for the peripheral vascular and neurovascular markets, announced preliminary six-month results from the AAA-SHAPE Safety Trial. Data will be presented during the 49th Annual VEITH Symposium in New York City on Tuesday, November 15, 2022. AAA-SHAPE is […]
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to improving patients’ lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the 12-month results of the DETOUR 2 trial during a late-breaking clinical trial session at the 2022 VIVA Vascular InterVentional Advances (VIVA) […]
CHOCOLATE TOUCH®, NEXT-GENERATION DRUG-COATED ANGIOPLASTY BALLOON FOR THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE RECEIVES FDA APPROVAL
SINGAPORE, Nov. 11, 2022 /PRNewswire/ — Genesis MedTech Group announced today that the Food and Drug Administration (FDA) has approved the Chocolate Touch® Drug-coated Balloon PTA Catheter, developed by TriReme Medical LLC, for the treatment of patients with peripheral artery disease in the superficial femoral artery and the popliteal artery. The Chocolate […]
ISHLT Expands Research Funding for Advanced Heart and Lung Disease: Applications Open Now
CHICAGO, Nov. 11, 2022 /PRNewswire/ –The International Society for Heart and Lung Transplantation (ISHLT) is now accepting applications for four research grants to be awarded during the first 2023 grant cycle, which concludes with the announcement of winners at the ISHLT Annual Meeting in Denver in April 2023. Applications for these grants will be accepted […]
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third […]
Acutus Medical Reports Third Quarter 2022 Financial Results
CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022. Recent Updates: Reported revenue of $3.6 million in the […]
HeartBeam Reports Third Quarter 2022 Financial Results
HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance Company on Track for Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, in Q4 2022 AIMIGo Technology Receives Two Additional Patents Company Plans to Broaden Product Portfolio Pipeline with Smartwatch Connectivity Management to Host […]



